RT Journal Article
SR Electronic
A1 Nichols, Emma Hitt
T1 Emerging Pharmacotherapies: The Future of Heart Failure Management
JF MD Conference Express
YR 2013
FD SAGE Publications
VO 13
IS 2
SP 34
OP 36
DO 10.1177/155989771302022
UL http://mdc.sagepub.com/content/13/2/34.abstract
AB Patients with heart failure (HF) often remain symptomatic and have a poor prognosis despite treatment with existing therapies [Cleland JG et al. Lancet 2011]. Several new therapeutic options are currently emerging for HF, including direct renin inhibitors, neprilysin inhibitors, selective If channel inhibitors, cardiac myosin activators, vasopressin receptor antagonists, and phosphodiesterase type 5 inhibitors. This article discusses clinical trial data for direct renin inhibitors and neprilysin inhibitors.